Nobel prize for the artemisinin and ivermectin discoveries: A great boost towards elimination of the global infectious diseases of poverty

Infectious Diseases of Poverty

Volumn 4, Issue 1, 2015, Pages

  Tambo, Ernest ^a,b,c,d   Khater, Emad I M ^e,f   Chen, Jun Hu ^g,h,i   Bergquist, Robert ^j   Zhou, Xiao Nong ^e,f,g  

^a Higher Institute of Public Health Sciences   (Cameroon)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c Africa Disease Intelligence and Surveillance   (Cameroon)

^d UNIVERSITY OF PRETORIA   (South Africa)

^e Public Health Pests Laboratory   (Saudi Arabia)

^f Ain Shams University   (Egypt)

^g CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^h BEIJING HOSPITAL   (China)

ⁱ WHO Collaborating Center for Occupational Health   (China)

^j Brastad   (Sweden)

more..

Author keywords

Artemisinin; Avermectin; Discovery; Intestinal helminths; Ivermectin; Lymphatic filariasis; Malaria; Nobel Prize; Poverty; Praziquantel; River blindness; Schistosomiasis

Indexed keywords

AMINOQUINOLINE DERIVATIVE; ARTEMISININ; CHLOROQUINE; IVERMECTIN; PRAZIQUANTEL; PYRIMETHAMINE PLUS SULFADOXINE; TRICLABENDAZOLE; ANTIINFECTIVE AGENT; ANTIPROTOZOAL AGENT; ARTEMISININ DERIVATIVE; AVERMECTIN;

CLONORCHIS; DERMATITIS; DRUG SURVEILLANCE PROGRAM; ECHINOCOCCOSIS; EDITORIAL; EYE INFLAMMATION; GEOGRAPHIC INFORMATION SYSTEM; HEALTH CARE ORGANIZATION; HELMINTHIASIS; HUMAN; INFECTION; LOWEST INCOME GROUP; LYMPHATIC FILARIASIS; MALARIA; ONCHOCERCIASIS; PLASMODIUM BERGHEI INFECTION; POVERTY; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SCHISTOSOMIASIS; WELLBEING; ANALOGS AND DERIVATIVES; ART; AWARDS AND PRIZES; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; GLOBAL HEALTH; HISTORY; PARASITOLOGY;

ANTI-INFECTIVE AGENTS; ANTIPROTOZOAL AGENTS; ARTEMISININS; COMMUNICABLE DISEASE CONTROL; COMMUNICABLE DISEASES; GLOBAL HEALTH; HISTORY, 21ST CENTURY; HUMANS; IVERMECTIN; NOBEL PRIZE;

EID: 85006220548     PISSN: 20955162     EISSN: 20499957     Source Type: Journal    
DOI: 10.1186/s40249-015-0091-8     Document Type: Editorial

References (57)

1. World Health Organization (WHO) 2013. Program for the elimination of neglected diseases in Africa (PENDA). 2016-2025. Accessed on 15 Oct 2015
2. WHO. Global technical strategy for malaria 2016-2030. 2015; ISBN 978 92 4 156499. http://apps.who.int/iris/bitstream/10665/176712/1/9789241564991_eng.pdf?ua=1&ua=1. accessed on 15th October 2015.
3. WHO. APOC strategic plan. www.who.int/apoc/en_apoc_strategic_plan_2013_ok.pdf , accessed 15 October 2015.
4. Boatin B. The Onchocerciasis Control Programme in West Africa (OCP). Ann Trop Med Parasitol. 2008;102 Suppl 1:13-7.
5. WHO. Accelerating work to overcome the global impact of neglected tropical diseases. A roadmap for implementation (http://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf ) accessed 24 October 2015.
6. Tu Y. The development of the antimalarial drugs with new type of chemical structure: Qinghaosu and Dihydro Qinghaosu. Southeast Asian J Trop Med Public Health. 2004;35:250-1.
7. Yu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med. 2011;17(10):1217-20. doi: 10.1038/nm.2471.
8. Su XZ, Miller LH. The discovery of artemisinin and the Nobel Prize in Physiology or Medicine. Sci China Life Sci. 2015 Oct 19. [Epub ahead of print]
9. Campbell WC. The genesis of the antiparasitic drug ivermectin. In: Weber RJ, Perkins DN, editors. Inventive Minds. New York: Oxford University Press; 1992. p. 194-214.
10. David H. Molyneux, Steve A. Ward. Reflections on the Nobel Prize for Medicine 2015 - The Public Health Legacy and Impact of Avermectin and Artemisinin. Trends in Parasitology. 2015 Vol 31; Available online 6 November 2015 In Press
11. Owens B. Nobel Prize goes to antiparasitic drug discoverers. Lancet. 2015;386(10002):1433. doi: 10.1016/S0140-6736(15)00455-9.
12. Omura S. Ivermectin: 25 years and still going strong. Int J Antimicrob Agents. 2008;31:91-8.
13. Antoine T, Fisher N, Amewu R, O'Neill PM, Ward SA, Biagini GA. Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential. J Antimicrob Chemother. 2014;69(4):1005-16.
14. Tambo E, Adedeji AA, Fang H, Chen Hu J, Zhou SS, Thang LH. Scaling up impact of malaria control programmes: a tale of events in Africa and People's Republic of China from 1960-2011. Inf Dis Poverty J. 2012;1(7):42.
15. http://www.un.org/millenniumgoals/2015_MDG_Report/pdf/MDG%202015%20PR%20Global.pdf (accessed 30 October 2015)
16. World Health Organization. Global action plan for malaria free world 2010. http://www.rollbackmalaria.org/microsites/gmap/1-3.html accessed 20th October 2015
17. Shah JA, Emina JB, Eckert E, Ye Y. Prompt access to effective malaria treatment among children under five in sub-Saharan Africa: a multi-country analysis of national household survey data. Malar J. 2015;14:329.
18. Sowunmi A, Fateye BA, Adedeji AA, Fehintola FA, Gbotosho GO, Happi TC, et al. Predictors of chloroquine or pyrimethamine-sulfadoxine treatment failure in children with acute uncomplicated falciparum malaria. An Trop Med and Parasitology. 2005;99:535-44.
19. Sharing knowledge and catalyzing research to achieve our eradication goal. http://www.malariaeradication.org/ accessed 2th November 2015
20. The malERA Consultative Group on Monitoring, Evaluation, and Surveillance. A Research Agenda for Malaria Eradication: Monitoring, Evaluation, and Surveillance. PLoS Med. 2011;8(1):e1000400. doi: 10.1371/journal.pmed.1000400. Published online 2011 January 25.
21. Anne M, Yoel L, Kara H. Malaria eradication: the economic, financial and institutional challenge. Malar J. 2008;7 Suppl 1:S11. doi: 10.1186/1475-2875-7-S1-S11. Published online 2008 December 11.
22. Xia ZG, Wang RB, Wang DQ, Feng J, Zheng Q, Deng CS, et al. China-Africa cooperation initiatives in malaria control and elimination. Adv Parasitol. 2014;86:319-37. doi: 10.1016/B978-0-12-800869-0.00012-3.
23. C-ORGo Q. Antimalaria studies on Qinghaosu. Chin Med J (Engl). 1979;92:811-6.
24. Julie T, Eisele TP, Steketee RW. Protective efficacy of malaria case management for preventing malaria mortality in children: a systematic review for the Lives Saved Tool. BMC Public Health. 2011;11 Suppl 3:S14. doi: 10.1186/1471-2458-11-S3-S14. Published online 2011 April 13.
25. Janette R, Mariëtte B, Anjo T, Lauterbach SB, Claire R, Dewaldt E, et al. Nowhere to hide: interrogating different metabolic parameters of Plasmodium falciparum gametocytes in a transmission blocking drug discovery pipeline towards malaria elimination. Malaria J. 2015;14:213.
26. Takala-Harrison S, Clark TG, Jacob CG, Cummings MP, Miotto O, Dondorp AM, et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci U S A. 2013;110(1):240-5. doi: 10.1073/pnas.1211205110. Published online 2012 December 17.
27. Philippe G, Vincent C, Guérin PJ, Adeline L, François N, Sébastien B, et al. Past and new challenges for malaria control and elimination: the role of operational research for innovation in designing interventions. Malar J. 2015;14:279.
28. Shannon Takala-Harrison, Miriam K. Laufer. Antimalarial drug resistance in Africa: key lessons for the future. Ann N Y Acad Sci. Author manuscript; available in PMC 2015 August 6
29. WWARN Artemisinin based Combination Therapy (ACT) Africa Baseline Study Group. Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. BMC Med. 2015;13:212.
30. Shah NK, Tyagi P, Sharma SK. The Impact of Artemisinin Combination Therapy and Long-Lasting Insecticidal Nets on Forest Malaria Incidence in Tribal Villages of India, 2006-2011. PLoS One. 2013;8(2):e56740.
31. Liwang C, Guiyun Y, Jetsumon S, Yaming C, Bin C, Xiaoguang C, et al. Malaria in the Greater Mekong Subregion: Heterogeneity and Complexity. Acta Trop. 2012;121(3):227-39.
32. Chaccour CJ, Kobylinski KC, Quique B, Teun B, Chris D, Pedro A, et al. Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination. Malar J. 2013;12:153.
33. Oliver S, Cohen JM, Hsiang MS, Kahn JG, Suprotik B, Linhua T, et al. Costs and financial feasibility of malaria elimination. Lancet. 2010;376(9752):1604-15.
34. Whitty CJM, Clare C, Evelyn A, Toby L, Staedke SG. Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. Malar J. 2008;7 Suppl 1:S7.
35. Gustavsen KM, Bradley MH, Wright AL. GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis. Ann Trop Med Parasitol. 2009;103 Suppl 1:S1-5.
36. World Health Organization. Report of the sixth meeting of the WHO Strategic and Technical Advisory Group for Neglected Tropical Diseases. WHO headquarters, Geneva. Geneva: World Health Organization; 2013. Available: http://www.who.int/neglected_diseases/NTD_STAG_Report_2013.pdf. Accessed 14 October, 2015.
37. Ramaiah KD, Ottesen EA. Progress and Impact of 13 Years of the Global Programme to Eliminate Lymphatic Filariasis on Reducing the Burden of Filarial Disease. PLoS Negl Trop Dis. 2014;8(11):e3319. doi: 10.1371/journal.pntd.0003319.
38. Liese BH, Schubert L. Official development assistance for health-how neglected are neglected tropical diseases? An analysis of health financing. International Health. 2009;1:141-7.
39. Montresor A, Dai Tran C, Mouth S, Reiko T, Chitsavang C, Hanne S, et al. Large-Scale Preventive Chemotherapy for the Control of Helminth Infection in Western Pacific Countries: Six Years Later. PLoS Negl Trop Dis. 2008;2(8):e278.
40. Turner HC, Walker M, Churcher TS, Osei-Atweneboana MY, Biritwum N-K, Hopkins A, et al. Reaching the London Declaration on Neglected Tropical Diseases Goals for Onchocerciasis: An Economic Evaluation of Increasing the Frequency of Ivermectin Treatment in Africa. Clin Infect Dis. 2014;59(7):923-32.
41. Ken G, Adrian H, Mauricio S. Onchocerciasis in the Americas: from arrival to (near) elimination. Parasit Vectors. 2011;4:205.
42. Ichimori K, King JD, Engels D, Yajima A, Mikhailov A, Lammie P, et al. Global Programme to Eliminate Lymphatic Filariasis: The Processes Underlying Programme Success. PLoS Negl Trop Dis. 2014;8(12):e3328.
43. Haoues A, Krajacich BJ, Meyers JI, Grubaugh ND, Brackney DE, Kobylinski KC, et al. Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments. Malar J. 2014;13:417.
44. Nörenberg W, Sobottka H, Hempel C, Plötz T, Fischer W, Schmalzing G, et al. Positive allosteric modulation by ivermectin of human but not murine P2X7 receptors. Br J Pharmacol. 2012;167(1):48-66.
45. Diawara L, Traore MO, Badji A, Bissan Y, Doumbia K, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis. 2009;3:e497.
46. Turner HC, Osei-Atweneboana MY, Walker M, Tettevi EJ, Churcher TS, Asiedu O, et al. The Cost of Annual versus Biannual Community-Directed Treatment of Onchocerciasis with Ivermectin: Ghana as a Case Study. PLoS Negl Trop Dis. 2013;7(9):e2452.
47. World Malaria Day 2015. Three Community-Based Approaches to Save Women and Children. http://www.msh.org/blog/2015/04/24/world-malaria-day-2015-three-community-based-approaches-to-save-women-and-children accessed on 18th October 2015
48. McMahon JE, Kolstrup N. Praziquantel: a new schistosomicide against Schistosoma haematobium. Br Med J. 1979;2(6202):1396-8.
49. Evans D, Mcfarland D, Adamani W, Eigege A, Miri E, Schulz J, et al. Cost-effectiveness of triple drug administration (TDA) with praziquantel, ivermectin and albendazole for the prevention of neglected tropical diseases in Nigeria. Ann Trop Med Parasitol. 2011;105(8):537-47.
50. Meredith SEO, Catherine C, Amazigo UV. Empowering communities in combating river blindness and the role of NGOs: case studies from Cameroon, Mali, Nigeria, and Uganda. Health Res Policy Syst. 2012;10:16. doi: 10.1186/1478-4505-10-16. Published online 2012 May 10.
51. Linehan M, Hanson C, Weaver A, Baker M, Kabore A, et al. Integrated implementation of programs targeting neglected tropical diseases through preventive chemotherapy: proving the feasibility at national scale. Amer J Trop Med Hyg. 2011;84:5-9.
52. Plaisier AP, Alley ES, Boatin BA, Van Oortmarssen GJ, Remme H, et al. Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa. J Infect Dis. 1995;172:204-10.
53. Panic G, Vargas M, Scandale I, Keiser J. Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni. PLoS Negl Trop Dis. 2015;9(7):e0003962.
54. WHO, Food borne trematodiases. Factsheet. http://www.who.int/mediacentre/factsheets/fs368/en/ (accessed 30 October 2015)
55. WHO. Schistosomiasis: A major public health problem http://www.who.int/schistosomiasis/en/ (accessed 30 October 2015)
56. WHO. Foodborne trematode infections. http://www.who.int/foodborne_trematode_infections/en/ (accessed 30 October 2015)
57. Russell Stothard J, Sousa-Figueiredo JC, Betson M, Bustinduy A, Reinhard-Rupp J. Schistosomiasis in African infants and preschool children: let them now be treated. Trends Parasitol. 2013;29(4):197-205.